Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59 results about "Epithelial cell adhesion molecule" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca²⁺-independent homotypic cell–cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies.
Anti-EpCAM antibodies
InactiveCN102549017AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHeavy chainCam
Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (Ep CAM) and display certain advantages over known antibodies which bind to Ep CAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-Ep CAM antibodies are also provided.
Owner:奥菲技术科学研究院
Immunomagnetic microsphere used for capturing circulating tumor cells in peripheral blood
ActiveCN103911345APlay a role in magnifying the sizeHigh selectivityElectrical/wave energy microorganism treatmentTumor/cancer cellsCirculating cancer cellSpecific antibody
The invention discloses an immunomagnetic microsphere used for capturing circulating tumor cells in peripheral blood. The immunomagnetic microsphere comprises a magnetic microsphere, wherein an epithelial cell specific antibody used for specifically recognizing and capturing circulating tumor cells is coupled on the magnetic microsphere. The epithelial cell specific antibody is selected according to a target tumor cell needed to be captured, for example, when the MCF (michigan cancer foundation)-7 cell is needed to be captured, the epithelial cell specific antibody selects an anti-EpCAM (epithelial cell adhesion molecule) antibody. The invention further discloses a method for capturing circulating tumor cells in peripheral blood by utilizing the immunomagnetic microsphere. The immunomagnetic microsphere disclosed by the invention is modified by the epithelial cell specific antibody, so that high-selectivity and high-specificity capturing for the target cell can be realized. The magnetic microsphere can achieve dimension amplifying effect, is used for realizing film separation with high recovery, and further can be used for magnetic separation operation to realize high-purity capturing. The immunomagnetic microsphere and the capturing method thereof can be used for early diagnosis of a cancer patient and prediction of therapeutic response.
Owner:BRILLIANCE BIO TECH CO LTD +1
CTC (circulating tumor cell) capturing and purifying substrate based on chitosan nanoparticles and preparation method of CTC capturing and purifying substrate
ActiveCN106148315AGood compatibilityImprove matchOn/in organic carrierChitosan nanoparticlesPolyethylene glycol
The invention discloses a CTC (circulating tumor cell) capturing and purifying substrate based on chitosan nanoparticles as well as a preparation method and an application of the CTC capturing and purifying substrate. Chitosan with good cytocompatibility is selected for constructing a three-dimensional nanostructure 'soft' substrate, anti-adhesion molecules such as PEG (polyethylene glycol) molecules are introduced to reduce the nonspecific adhesion of cells on an interface, affine CTC capturing molecules such as EpCAM (epithelial cell adhesion molecule) aptamers are used for high-specific capturing of CTCs, and the purity of target cells is further improved in an in-situ culturing manner of the captured cells on the basis of proliferation attribute difference of the CTCs and blood cells. The CTC capturing and purifying substrate has good cytocompatibility and can keep the activity of the captured cells, a preparation process is simple and convenient, the cost is low, in-situ culturing and purification of the captured cells can be realized, and large-scale implementation is easy to realize.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
Antibody coupled mesoporous silica/mifepristone nanometer preparation
ActiveCN105125510AAvoid stickingInhibitory activityOrganic active ingredientsPowder deliveryEngineeringMesoporous silica
The invention discloses an antibody coupled mesoporous silica / mifepristone nanometer preparation and a preparing method and application thereof. The preparation is prepared from mesoporous silica nanoparticles (MSN), mifepristone (MIF) and epithelial cell adhesion molecule antibodies (anti-EpCAM, aE), MIF is carried by MSN, and the surface of the MSN is covalently modified by aE. The ntibody coupled mesoporous silica / mifepristone nanometer preparation can recognize in a targeting mode, restrain activity of circular tumor cells (CTCs), restrain adhesion between the CTCs and endangium, disturb a tumor metastasis process and remarkably restrain tumor metastasis.
Owner:FUZHOU UNIV
Aptamer EpCAM (epithelial cell adhesion molecule) Ccut of EpCAM and preparation method thereof
ActiveCN103387988AMaintain native conformationNo toxicityMicrobiological testing/measurementDNA preparationProtein targetNeural cell adhesion molecule
Owner:XIAMEN UNIV
Joint application of three types of monoclonal antibody-coupled immunomagnetic beads to sorting tumor cells
ActiveCN105087493AIncrease coverageHigh efficiency in sorting tumorsTumor/cancer cellsAntiendomysial antibodiesOncology
The invention discloses joint application of three types of monoclonal antibody-coupled immunomagnetic beads to sorting tumor cells and a method for sorting breast cancer tumor cells. The three types of monoclonal antibody-coupled immunomagnetic beads include anti-HLA-G (human leukocyte antigen-G) monoclonal antibody-coupled immunomagnetic beads, anti-EpCAM (epithelial cell adhesion molecule) monoclonal antibody-coupled immunomagnetic beads and anti-CK8 / 18 (casein kinase 8 / 18) monoclonal antibody-coupled immunomagnetic beads. The joint application and the method have the advantages that the three types of jointly applied antibody-coupled immunomagnetic beads are high in breast cancer tumor cell enrichment ratio and good in sensitivity and repeatability, and the relevant tumor cells can be detected; the three types of immunomagnetic beads (the anti-EpCAM immunomagnetic beads, the anti-HLA-G immunomagnetic beads and the anti-CK8 / 18 immunomagnetic beads) are jointly applied to enriching the tumor cells, so that the circulating tumor cell coverage rate can be increased to the greatest extent, the enrichment ratio can reach 80%, and a technology is international pioneer; the tumor cell enrichment specificity and sensitivity can be particularly guaranteed owing to usage of the anti-HLA-G monoclonal antibody-coupled immunomagnetic beads.
Owner:济南红枫叶生物科技有限公司
Nucleic acid aptamer of epithelial cell adhesion molecule and preparation method thereof
ActiveCN102827845AMaintain native conformationNo toxicityMicrobiological testing/measurementBiological testingProtein targetSingle strand dna
The invention relates to a nucleic acid, in particular to a nucleic acid aptamer of the epithelial cell adhesion molecule and a preparation method thereof. The invention provides a high-specificity and high-affinity nucleic acid aptamer of the epithelial cell adhesion molecule EpCAM and a preparation method and applications thereof. The nucleic acid aptamer of the epithelial cell adhesion molecule EpCAM is of the G-quadruplex structure or the stem-loop structure. The preparation method comprises the following steps: designing and synthetizing a single-stranded DNA (deoxyribonucleic acid) random oligonucleotide library, screening the target oligonucleotide sequence, and identifying the binding specificity and affinity of the sequence to the target protein through the flow cytometry. The screened nucleic acid aptamer is non-toxic, has small molecular weight and good permeability, is easy in synthesis and marking and can only perform specific identification to the EpCAM protein and perform specific identification and specific expression to the cell line of the EpCAM protein; and the nucleic acid aptamer can not identify the cell line which does not express the protein.
Owner:苏州德运康瑞生物科技有限公司
Magnetic material for efficiently detecting circulating tumor cell and preparation method of magnetic material
ActiveCN107858144ANarrow particle size distributionHigh saturation magnetizationOrganic/organic-metallic materials magnetismTumor/cancer cellsBiocompatibility TestingSuperparamagnetism
The invention provides a magnetic material for efficiently detecting a circulating tumor cell and a preparation method of the magnetic material. The preparation method comprises the steps of: (1) allowing hyaluronic acid, 1-(3-dimethylamino propyl)-3-ethyl-carbodiimide hydrochloride, 1-hydroxybenzotriazole, cysteamine hydrochloride and dithiothreitol to react to prepare HA-SH, (2) grafting rhodamine onto HA-SH to prepare RhB-HA-SH, (3) allowing an Fe3O4 nanoparticle, RhB-HA-SH and H2O2 to react to prepare superparamagnetic fluorescent HA-SH, and (4) allowing superparamagnetic fluorescent HA-SH, 1-(3-dimethylamino propyl)-3-ethyl-carbodiimide hydrochloride, 1-hydroxybenzotriazole, PEG-FA and anti-EpCAM (epithelial cell adhesion molecule) to perform antibody reaction to prepare the magneticmaterial. The magnetic material is high in saturation magnetization, and good in magnetic response and biocompatibility, can achieve specific binding with the circulating tumor cell and has certain universality.
Owner:SICHUAN UNIV
Preparation method of EpCAM (Epithelial Cell Adhesion Molecule) antibody immunomagnetic beads
The invention discloses a preparation method of EpCAM (Epithelial Cell Adhesion Molecule) antibody immunomagnetic beads. The preparation method comprises the following specific steps: synthesizing oleic acid-Fe3O4; preparing Fe3O4 / PVAc (Polyvinyl Acetate) magnetic microspheres; preparing (Fe3O4 / PVA) / SiO2 magnetic microspheres; adding aminated magnetic nanoparticles into a PBS (Polybutylene Succinate) solution of glutaraldehyde and stirring for 3h; modifying an aldehyde-group functional group on the surfaces of the magnetic particles through a Schiff base formed between an amino group and an aldehyde group; after finishing reaction, separating out the particles from a reaction medium by utilizing an external magnetic field and dispersing the particles into the PBS solution; carrying out hydrazino modification on an antibody: adding a dimethylformamide solution containing p-hydrazone pyridine formic acid N-hydroxysuccinyl imide into an EpCAM antibody solution; after reacting for 2h, purifying by utilizing an ultra-filtration column to obtain a hydrazino-modified EpCAM antibody; preparing the immunomagnetic beads: mixing the aldehyde-group-modified magnetic microspheres and the hydrazino modified EpCAM antibody and mixing to obtain the EpCAM antibody immunomagnetic beads of EpCAM antibody coupled magnetic microspheres. The EpCAM antibody immunomagnetic beads disclosed by the invention have the advantages of good stability, strong specificity and the like.
Owner:安徽安龙基因科技有限公司
Bispecific antibody against epithelial cell adhesion molecule (EpCAM) and T-cell antigen
The invention provides a bispecific antibody, including: (1) a first functional domain bonding with EpCAM; (2) a second functional domain bonding with CD3; and (3) a linker connecting the first functional domain with the second functional domain; wherein the first functional domain includes at least one light chain variable region and at least one heavy chain variable region, the light chain variable region includes three complementary determining regions consisting of CDR-L1: RASQDISNYLN, CDR-L2: YTSRLHS and CDR-L3: QQGSTLPYT, and the heavy chain variable region includes three complementary determining regions consisting of CDR-H1: GYTFTYYGMN, CDR-H2: WINTYTGEPTYGDDFKG and CDR-H3: TGRATSFDY.
Owner:SHANGHAI INST OF ONCOLOGY
Preparing method for nano-composite fiber film with functions of carrying medicine and killing cancer cells
The invention provides a preparing method for a nano-composite fiber film with the functions of carrying medicine and killing cancer cells. The nano-composite fiber film has the function of capturing and killing circulating cancer cells. The preparing method includes the steps that nano-composite fibers are prepared into the nano-composite fiber film with carboxyl functional groups or carboxyl functional groups generated through modification with the electrostatic spinning technology, the film is carried with anticancer medicine, and then anti-epithelial cell adhesion molecule protein (anti-EpCAM) is grafted to the surface of the nano-fiber film. The nano-composite fiber system prepared with the method has the advantage that the dual functions that the circulating cancer cells can be captured and killed at the same time are achieved; the nano-composite fiber system carrying the anticancer medicine has the advantage that circulating cancer is specifically captured through the specificity; the nano-composite fiber system can automatically release the anticancer medicine through the PH value of the ambient environment of the cancer cells, and the aim that the circulating cancer cells are killed is achieved.
Owner:UNIV OF SCI & TECH BEIJING
Preparation method and kit for dendritic cell vaccine loaded by tumor specific antigenic epitope polypeptide
InactiveCN103800897ACure recurrenceCure metastasesAntibody medical ingredientsMacromolecular non-active ingredientsHuman leucocyte antigenEpitope
The invention provides a preparation method for a dendritic cell vaccine loaded by a tumor specific antigenic epitope polypeptide. The method comprises the following steps: adopting a human leucocyte antigen A201 positive epitope of an epithelial cell adhesion molecule identified by tumor specific expression, namely a polypeptide composed of amino acid sequences represented by any one of SEQ ID NO.1-6; loading dendritic cells by using the polypeptide of any one of the SEQ ID NO.1-6 to prepare the dendritic cell vaccine. The dendritic cell vaccine can be used for initiating a very strong target anti-tumor cytotoxic T lymphocyte effect. The invention further provides a kit for preparing the dendritic cell vaccine loaded by the tumor specific antigenic epitope polypeptide.
Owner:李金珍
EpCAM TARGETED POLYPEPTIDES, CONJUGATES THEREOF, AND METHODS OF USE THEREOF
ActiveUS20180251524A1High binding affinityConnective tissue peptidesAntibody mimetics/scaffoldsMolecular imagingMolecular Targeted Therapies
Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.
Owner:RGT UNIV OF MINNESOTA
Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer
InactiveUS20120213805A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAdenocarcinomaToxin Conjugates
The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer.
Owner:FAULSTICH HEINZ +3
Immunomagnetic nano-particle for visual capture and release of circulating tumor cells, and preparation method thereof
ActiveCN109100511AHigh enrichment efficiencyImplement featuresInorganic material magnetismBiological testingFluorescencePolyethylene glycol
The invention discloses an immunomagnetic nano-particle with fluorescent properties and a preparation method and application thereof. The method comprises the following steps: using magnetic nano-particle Fe3O4 as a core, constructing a magnetic nano-particle with fluorescence properties by depositing a quantum dot layer on the surface of the magnetic nano-particle Fe3O4, and further introducing the anti-epithelial cell adhesion molecule antibody and the aminated polyethylene glycol molecule into the fluorescent magnetic nano-particle to obtain an immunomagnetic nano-particle. The immunomagnetic nano-particle enables rapid specific capture and release of circulating tumor cells. In addition, the quantum dot-labeled magnetic nano-particle enables visualization of capture and release processes of circulating tumor cells.
Owner:SICHUAN UNIV
Nucleic acid aptamer of epithelial cell adhesion molecule (EpCAM) screened in human plasma and preparation method and application thereof
ActiveCN110004147AEfficient captureGood affinity and stabilityMicrobiological testing/measurementDNA preparationAptamerScreening method
The invention discloses a nucleic acid aptamer of an epithelial cell adhesion molecule (EpCAM) screened in human plasma and a preparation method and application thereof. The nucleic acid aptamer capable of conducting highly specific recognition and high-affinity binding on the epithelial cell adhesion molecule (EpCAM) in the complex physiological environment of the human plasma is provided, a nucleic acid aptamer screening method making the human plasma simulate the complex physiological environment is developed, and the nucleic acid aptamer which is directly applied to capture of CTCs in peripheral blood can be obtained; the finally obtained aptamer has the advantages of being easy to obtain, low in cost, not prone to inactivation, free of immunogenicity or toxicity and the like, by meansof the sequences, specific recognition and capture of CTCs of tumor cell lines of EpCAM protein and expression EpCAM protein are achieved; in addition, the nucleic acid aptamer has high affinity in the human plasma, application of the nucleic acid in biological analysis and clinical medicine is ensured, and the aptamer is expected to serve as a molecule recognition tool of CTCs detection to be applied to liquid biopsies.
Owner:XIAMEN UNIV
Aptamer EpCAM (epithelial cell adhesion molecule) B of EpCAM and preparation method thereof
ActiveCN103387990AMaintain native conformationNo toxicityMicrobiological testing/measurementDNA preparationAptamerProtein target
The invention provides an aptamer EpCAM (epithelial cell adhesion molecule) B of an EpCAM as well as a preparation method and application thereof, relating to nucleic acids. The aptamer has high specificity and affinity. The aptamer has a G tetramer structure or a stem-loop structure. The preparation method comprises the steps of designing and synthesizing a single-stranded DNA (deoxyribonucleic acid) random oligonucleotide bank, screening a target oligonucleotide sequence, and identifying the target protein binding specificity and affinity of the target oligonucleotide sequence by a flow analysis method. The screened aptamer does not have toxicity, has small molecular weight and good permeability, is easy to synthesize and label, only specifically identifies EpCAM proteins and cell lines expressing the EpCAM proteins, and does not have a function of identifying the cell lines which do not express the proteins.
Owner:XIAMEN UNIV
Human Source antibody for anti CD20 and epithelial cell adhesion molecule
A humanized antibody to CD20 and epithelial cell adhesion molecule (EpCAM), and its preparing process and application are disclosed. Said antibody has high affinity and specificity to CD20 and EpCAM.
Owner:CHINESE NAT HUMAN GENOME CENT AT SHANGHAI
Bispecific antigen binding molecule for a costimulatory TNF receptor
ActiveUS20200231691A1Improve cell activityEliminate side effectsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsReceptorAntigen binding
The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
Owner:F HOFFMANN LA ROCHE & CO AG
Kit for detecting blood circulation tumor cells
InactiveCN104774959AAccurately reflect the levelImprove detection efficiencyMicrobiological testing/measurementRNA extractionPolymerase L
The technical scheme of the invention discloses a method for performing epithelial cell adhesion molecule expression detection on peripheral blood of lung cancer patients by the utilization of combining an MGB probe with a fluorescent quantitative polymerase chain reaction method, and therefore a circulating tumor cell level in the body is reflected. The method of the kit for detecting blood circulation tumor cells comprises the steps that RNA extraction and cDNA reverse transcription are performed on an objective specimen needing to be detected, then the MGB probe is used to perform fluorescent quantitative polymerase chain amplification reaction, finally the fluorescence intensity is detected by a fluorescent quantitative polymerase chain amplification reaction apparatus, and the epithelial cell adhesion molecule expression level is obtained. The kit for detecting the blood circulation tumor cells has the advantages of being high in sensitivity and high in specificity, meanwhile, the high through-put advantage of a common polymerase chain reaction method is inherited, the detection efficiency is improved, and the detection cost is reduced.
Owner:刘志东 +2
Body fluid tumor cell DNA extraction kit
PendingCN111487404AThe test result is accurateImprove the detection effectMaterial analysisCell extractionLysis
The invention provides a body fluid tumor cell DNA extraction kit. The body fluid tumor cell DNA extraction kit is used for extracting DNA of tumor cells which are separated from solid tumors and enter body fluid, and is characterized by comprising specific immunomagnetic beads, a magnetic separation frame, a lysis solution, a first washing liquid, a second first washing liquid and an eluant, wherein the specific immunomagnetic beads are used for capturing the body fluid tumor cells from the body fluid; the magnetic separation frame is used for attracting the specific immunomagnetic beads through magnetic force; the lysis solution is used for carrying out cell lysis on the captured body fluid tumor cells; the first washing liquid is used for washing the lysed body fluid tumor cells for thefirst time; the second washing liquid is used for washing the body fluid tumor cells subjected to the first washing for the second time; and the specific immunomagnetic beads are magnetic nano microspheres modified by epithelial cell adhesion molecules.
Owner:猎源(上海)生物医药科技有限公司
Human IL2 (interleukin 2) and anti-EpCAM (epithelial cell adhesion molecule) single-chain antibody fusion protein and application thereof
InactiveCN108503714ALow toxicityImprove efficacyPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseProtein C
The invention relates to an anti-EpCAM (epithelial cell adhesion molecule) single-chain antibody conjugated and genetic engineering optimized IL2 (interleukin 2) fusion protein. The molecular weight is about 46 Kda, an IgG structure is replaced with the single-chain antibody, the molecular structure is smaller, and steric hindrance is reduced, so that the protein has more flexible space structureand higher biological activity titer. The fusion protein has the affinity as high as that of EpCAM protein and stronger T cell proliferation promoting capability; the fusion protein can be crosslinkedwith the EpCAMs on tumor cell surfaces and interleukin receptors on T cell surfaces, promote recognition of immune cells and target molecule expression cells and signal transduction, trigger recognition and killing of tumor cells by the immune cells and can further activate T cell proliferation promoting interleukin receptor signals, and further has better lymphocyte tumor infiltration promotingcapability. The fusion protein can serve as a new-generation biological drug to be applied to treatment of tumor diseases or serve as a tool protein for in-vitro detection.
Owner:ZHEJIANG K2 ONCOLOGY CO LTD
Anti-epithelial cell adhesion molecule (EpCAM) antibodies and methods of use thereof
ActiveCN104168916AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCancer cellAntigen Binding Fragment
An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM, said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and(c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.
Owner:ACAD SINIC
Silica nano material delivery system for capturing and treating circulating tumor cells
InactiveCN108186603AThe hole size can be adjustedLarge specific surface areaOrganic active ingredientsGenetic material ingredientsMicrosphereMesoporous silica
The invention provides a silica nano material delivery system for capturing and treating circulating tumor cells. The silica nano material is prepared from a magnetic mesoporous silica nano microsphere, a siRNA (small interfering Ribonucleic Acid) medicine and a targeting antibody. The circulating tumor cells (CTCs) are used as liquid biopsy specimens representing a primary tumor, and help to carry out histological identification in real-time and noninvasive manners. The silica nano material delivery system, based on loading the siRNA medicine into the magnetic mesoporous silica nano (FE3O4-MSNs (Mesoporous Silica Nanoparticles)) microsphere and through modification, can be used for recognizing and binding the targeting antibodies (modified by double antibodies CD133 and an EPCAM (Epithelial Cell Adhesion Molecule)) of surface biomarkers of the CTCs; a brand-new FE3O4-MSNs_siRNA@CD133-EPCAM co-loading system is finally developed, and the system can be used for preliminarily realizing the targeting capturing and inhibition on the CTCs.
Owner:上海菱蓝生物科技有限公司
Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection
ActiveUS20200182877A1Accurate identificationEfficient captureImmunoglobulins against cell receptors/antigens/surface-determinantsDisease diagnosisOncologyThelial cell
Methods and kits for detecting hepatocellular carcinoma recurrence or metastasis, and of measuring markers of hepatocellular carcinoma, including markers of hepatocellular carcinoma recurrence or metastasis, in a blood sample obtained from a subject by (a) isolating circulating tumor cells (CTCs) by contacting a blood sample obtained from the subject with a set of capture antibodies, wherein the capture antibodies specifically bind asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM); (b) contacting the isolated CTCs with an antibody that specifically binds vimentin; and (c) measuring the number of vimentin-positive CTC.
Owner:RGT UNIV OF CALIFORNIA
EpCAM (epithelial cell adhesion molecule) Single-domain antibody E6
ActiveCN108530538ASmall molecular weightStrong specificityBacteriaImmunoglobulins against cell receptors/antigens/surface-determinantsNeural cell adhesion moleculeProkaryotic expression
The invention belongs to the field of molecular biology and particularly relates to EpCAM (epithelial cell adhesion molecule) single-domain antibody E6. A single-domain heavy-chain antibody library capable of specifically binding with target antigen EpCAM is screened from a camelid source immunized single-domain heavy-chain antibody library by means of a phage display technique; a gene sequence toencode the antibody is cloned to a prokaryotic expression vector so as to obtain the efficient-expression EpCAM single-domain antibody. The specific binding performance of the single-domain antibodycan be significantly improved, and basis is laid for immuno-guided clinical therapy of EpCAM.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Polypeptide-albumin coupling drug and preparing method and application thereof
InactiveCN105440112AStrong specificityLethalOrganic active ingredientsAlbumin peptidesTargeted therapyTarget therapy
The invention provides a polypeptide-albumin coupling drug for treating cancer. Polypeptide can be specifically bonded with epithelial cell adhesion molecules (EpCAM), and Michael addition reaction can be conducted between the terminal modification 3-maleimide group (BMPA) and free cysteine of human serum albumin; the polypeptide-albumin coupling drug is formed through chemical coupling of an albumin binding type chemotherapy drug and polypeptide, and preferably, the albumin binding type chemotherapy drug is Abraxane. The polypeptide-albumin coupling drug has high specificity, has extremely high cancerous cell killing ability, provides a feasible method and technical means for targeted therapy of cancer, and has significant value in targeted therapy of tumor.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Preparation method and device for novel labeling technique of cervix cancer cells
Owner:GUANGZHOU HONGQI OPTICAL INSTR TECH
Light chain and heavy chain variable region of FMU-EPCAM-2D7 monoclonal antibody
InactiveCN101899112ASpecific bindingProving uniquenessImmunoglobulins against animals/humansGenetic engineeringBALB/cGenetic engineering
The invention discloses light chain and heavy chain variable regions of an FMU-EPCAM(Epithelial Cell Adhesion Molecule)-2D7 monoclonal antibody, wherein an amino acid sequence of the light-chain variable region of the FMU-EPCAM-2D7 monoclonal antibody is disclosed as SEQ ID NO.1; and an amino acid sequence of the heavy-chain variable region is disclosed as SEQ ID NO.2. A group of mouse antihuman EPCAM monoclonal antibodies are prepared by recombinating human EPCAM immune BALB / c mousses, ascitic fluid is prepared by screening hybridoma cell lines which can stably secrete high-affinity antihuman EPCAM monoclonal antibodies, and the high-affinity antihuman EPCAM monoclonal antibodies can be obtained. The invention ensures the uniqueness and a CDR sequence thereof of a gene sequence and a corresponding protein sequence and provides a support for antihuman EPCAM chimerisms or humanized genetic engineering antibodies.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Aptamer EpCAM (epithelial cell adhesion molecule) D of EpCAM and preparation method thereof
ActiveCN103387989AMaintain native conformationNo toxicityMicrobiological testing/measurementDNA preparationProtein targetNeural cell adhesion molecule
The invention provides an aptamer EpCAM (epithelial cell adhesion molecule) D of an EpCAM as well as a preparation method and application thereof, relating to nucleic acids. The aptamer has high specificity and affinity. The aptamer has a G tetramer structure or a stem-loop structure. The preparation method comprises the steps of designing and synthesizing a single-stranded DNA (deoxyribonucleic acid) random oligonucleotide bank, screening a target oligonucleotide sequence, and identifying the target protein binding specificity and affinity of the target oligonucleotide sequence by a flow analysis method. The screened aptamer does not have toxicity, has small molecular weight and good permeability, is easy to synthesize and label, only specifically identifies EpCAM proteins and cell lines expressing the EpCAM proteins, and does not have a function of identifying the cell lines which do not express the proteins.
Owner:XIAMEN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com